カテゴリ： Allied Market Research, 世界, 医療/バイオ

勃起不全治療薬のグローバル市場（2023-2032）：シルデナフィル、タダラフィル、ウデナフィル、アバナフィル、その他

■ 英語タイトル：Erectile Dysfunction Drugs Market By Products (Sildenafil, Tadalafil, Udenafil, Avanafil , Others), By Mode of Administration  (Oral Medication , Injectable Medication ), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP102）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP102
■ 発行日：2023年4月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：417
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[勃起不全治療薬のグローバル市場（2023-2032）：シルデナフィル、タダラフィル、ウデナフィル、アバナフィル、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

勃起不全治療薬市場は2022年に26億ドルと評価され、2023年から2032年までの年平均成長率は6.5%で、2032年には51億ドルに達すると予測されています。勃起不全（ED）は、あらゆる年齢の男性に影響を及ぼす一般的な性的健康状態です。勃起不全は、性交渉に十分な勃起が得られない、または維持できない状態と定義されます。勃起不全（ED）は、多くの場合、高血圧、糖尿病、心臓病などの基礎疾患によって引き起こされます。勃起不全（ED）の原因となるその他の要因には、ストレス、不安、うつ病、神経損傷、特定の薬剤、喫煙や飲酒などの生活習慣があります。勃起不全（ED）の治療法には、薬物療法、生活習慣の改善、心理カウンセリングなどがあります。
勃起不全治療薬市場の成長を促進する主な要因は、糖尿病、高血圧、肥満などの慢性疾患の有病率の増加、インドや中国などの発展途上国における勃起不全治療に関連する利点に関する認知度の上昇が市場の成長を後押ししています。加えて、座りがちなライフスタイルの増加や、勃起不全症例の急増は、世界中で市場の成長をさらに後押ししています。例えば、米国国立衛生研究所によると、2022年、勃起不全（ED）は米国で一般的な症状であり、米国では毎年約3,000万人の男性が罹患しています。
しかし、勃起不全治療薬に伴う目のかすみ、鼻づまり、顔面紅潮などの副作用や、勃起不全に対する一般住民の認識や知識の不足が、今後数年間の市場成長の妨げになると予想されています。逆に、勃起不全治療における研究開発活動の増加や最新の製品承認は、近い将来の市場成長に有利な機会を提供すると予想されます。

勃起不全治療薬市場は、製品、投与方法、流通チャネル、地域によって区分されます。製品ベースでは、市場はシルデナフィル、アバンフィル、タダラフィル、ウデナフィル、その他に分類されます。投与方法に基づいて、市場は経口薬と注射薬に二分されます。流通チャネル別では、病院薬局、小売薬局、オンライン薬局に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、欧州のその他地域）、アジア太平洋地域（中国、日本、オーストラリア、インド、韓国、アジア太平洋のその他地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、LAMEAのその他地域）の市場を分析します。
本レポートに掲載されている主要企業は、Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi, Inc, Sun Pharmaceutical Industries Ltd., Bayer AG, Vivus LLC., Adamed Pharma, Glenmark Pharmaceuticals Limited, and Cipla Ltdです。

ステークホルダーにとっての主なメリット
本レポートは、勃起不全治療薬市場の2022年から2032年までの市場セグメント、現在の動向、予測、市場ダイナミクスを定量的に分析し、勃起不全治療薬市場の有力な機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
勃起不全治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
勃起不全治療薬市場の細分化に関する詳細な分析は、市場機会を決定するのに役立ちます。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
勃起不全治療薬の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
製品別
シルデナフィル
タダラフィル
ウデナフィル
アバナフィル
その他

投与方法別
経口薬
注射剤

流通経路別
病院薬局
小売薬局
オンライン薬局

地域別
北米
アメリカ
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Adamed
○ Bayer AG
○ Cipla Ltd
○ Eli Lilly and Company
○ Glenmark Pharmaceuticals Limited
○ Pfizer Inc.
○ Sanofi
○ Sun Pharmaceutical Industries Limited
○ Teva Pharmaceutical Industries Ltd.
○ Vivus LLC.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：勃起不全治療薬市場、製品別
第5章：勃起不全治療薬市場、投与方法別
第6章：勃起不全治療薬市場、流通チャネル別
第7章：勃起不全治療薬市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of erectile dysfunction
3.4.1.2. Rise in the prevalence of psychological disorders

3.4.2. Restraints
3.4.2.1. Side effects associated with erectile dysfunction drugs

3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS
4.1. Overview
4.1.1. Market size and forecast
4.2. Sildenafil
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Tadalafil
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Udenafil
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Avanafil 
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION 
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral Medication 
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injectable Medication 
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacy
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail Pharmacy
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacy
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: ERECTILE DYSFUNCTION DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Products
7.2.3. Market size and forecast, by Mode of Administration 
7.2.4. Market size and forecast, by Distribution Channels
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Products
7.2.5.1.3. Market size and forecast, by Mode of Administration 
7.2.5.1.4. Market size and forecast, by Distribution Channels
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Products
7.2.5.2.3. Market size and forecast, by Mode of Administration 
7.2.5.2.4. Market size and forecast, by Distribution Channels
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Products
7.2.5.3.3. Market size and forecast, by Mode of Administration 
7.2.5.3.4. Market size and forecast, by Distribution Channels
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Products
7.3.3. Market size and forecast, by Mode of Administration 
7.3.4. Market size and forecast, by Distribution Channels
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Products
7.3.5.1.3. Market size and forecast, by Mode of Administration 
7.3.5.1.4. Market size and forecast, by Distribution Channels
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Products
7.3.5.2.3. Market size and forecast, by Mode of Administration 
7.3.5.2.4. Market size and forecast, by Distribution Channels
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Products
7.3.5.3.3. Market size and forecast, by Mode of Administration 
7.3.5.3.4. Market size and forecast, by Distribution Channels
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Products
7.3.5.4.3. Market size and forecast, by Mode of Administration 
7.3.5.4.4. Market size and forecast, by Distribution Channels
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Products
7.3.5.5.3. Market size and forecast, by Mode of Administration 
7.3.5.5.4. Market size and forecast, by Distribution Channels
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Products
7.3.5.6.3. Market size and forecast, by Mode of Administration 
7.3.5.6.4. Market size and forecast, by Distribution Channels
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Products
7.4.3. Market size and forecast, by Mode of Administration 
7.4.4. Market size and forecast, by Distribution Channels
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Products
7.4.5.1.3. Market size and forecast, by Mode of Administration 
7.4.5.1.4. Market size and forecast, by Distribution Channels
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Products
7.4.5.2.3. Market size and forecast, by Mode of Administration 
7.4.5.2.4. Market size and forecast, by Distribution Channels
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Products
7.4.5.3.3. Market size and forecast, by Mode of Administration 
7.4.5.3.4. Market size and forecast, by Distribution Channels
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Products
7.4.5.4.3. Market size and forecast, by Mode of Administration 
7.4.5.4.4. Market size and forecast, by Distribution Channels
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Products
7.4.5.5.3. Market size and forecast, by Mode of Administration 
7.4.5.5.4. Market size and forecast, by Distribution Channels
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Products
7.4.5.6.3. Market size and forecast, by Mode of Administration 
7.4.5.6.4. Market size and forecast, by Distribution Channels
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Products
7.5.3. Market size and forecast, by Mode of Administration 
7.5.4. Market size and forecast, by Distribution Channels
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Products
7.5.5.1.3. Market size and forecast, by Mode of Administration 
7.5.5.1.4. Market size and forecast, by Distribution Channels
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Products
7.5.5.2.3. Market size and forecast, by Mode of Administration 
7.5.5.2.4. Market size and forecast, by Distribution Channels
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Products
7.5.5.3.3. Market size and forecast, by Mode of Administration 
7.5.5.3.4. Market size and forecast, by Distribution Channels
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Products
7.5.5.4.3. Market size and forecast, by Mode of Administration 
7.5.5.4.4. Market size and forecast, by Distribution Channels
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Eli Lilly and Company
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Teva Pharmaceutical Industries Ltd.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Sanofi
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Bayer AG
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Vivus LLC.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Adamed
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Glenmark Pharmaceuticals Limited
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Cipla Ltd
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Sun Pharmaceutical Industries Limited
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 02. ERECTILE DYSFUNCTION DRUGS MARKET FOR SILDENAFIL, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ERECTILE DYSFUNCTION DRUGS MARKET FOR TADALAFIL, BY REGION, 2022-2032 ($MILLION)
TABLE 04. ERECTILE DYSFUNCTION DRUGS MARKET FOR UDENAFIL, BY REGION, 2022-2032 ($MILLION)
TABLE 05. ERECTILE DYSFUNCTION DRUGS MARKET FOR AVANAFIL , BY REGION, 2022-2032 ($MILLION)
TABLE 06. ERECTILE DYSFUNCTION DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 08. ERECTILE DYSFUNCTION DRUGS MARKET FOR ORAL MEDICATION , BY REGION, 2022-2032 ($MILLION)
TABLE 09. ERECTILE DYSFUNCTION DRUGS MARKET FOR INJECTABLE MEDICATION , BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 11. ERECTILE DYSFUNCTION DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ERECTILE DYSFUNCTION DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ERECTILE DYSFUNCTION DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 14. ERECTILE DYSFUNCTION DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 19. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 20. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 21. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 22. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 23. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 24. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 25. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 26. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 27. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 28. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 29. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 30. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 31. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 33. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 34. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 35. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 36. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 37. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 38. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 39. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 40. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 41. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 42. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 43. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 44. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 45. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 46. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 54. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 55. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 56. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 57. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 58. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 59. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 60. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 61. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 62. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 72. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 73. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 74. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 75. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 76. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 77. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 78. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
TABLE 88. PFIZER INC.: KEY EXECUTIVES
TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
TABLE 90. PFIZER INC.: PRODUCT SEGMENTS
TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 92. PFIZER INC.: KEY STRATERGIES
TABLE 93. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 94. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 95. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 96. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 101. SANOFI: KEY EXECUTIVES
TABLE 102. SANOFI: COMPANY SNAPSHOT
TABLE 103. SANOFI: PRODUCT SEGMENTS
TABLE 104. SANOFI: PRODUCT PORTFOLIO
TABLE 105. BAYER AG: KEY EXECUTIVES
TABLE 106. BAYER AG: COMPANY SNAPSHOT
TABLE 107. BAYER AG: PRODUCT SEGMENTS
TABLE 108. BAYER AG: PRODUCT PORTFOLIO
TABLE 109. VIVUS LLC.: KEY EXECUTIVES
TABLE 110. VIVUS LLC.: COMPANY SNAPSHOT
TABLE 111. VIVUS LLC.: PRODUCT SEGMENTS
TABLE 112. VIVUS LLC.: SERVICE SEGMENTS
TABLE 113. VIVUS LLC.: PRODUCT PORTFOLIO
TABLE 114. ADAMED: KEY EXECUTIVES
TABLE 115. ADAMED: COMPANY SNAPSHOT
TABLE 116. ADAMED: PRODUCT SEGMENTS
TABLE 117. ADAMED: PRODUCT PORTFOLIO
TABLE 118. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 119. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 120. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 121. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 122. GLENMARK PHARMACEUTICALS LIMITED: KEY STRATERGIES
TABLE 123. CIPLA LTD: KEY EXECUTIVES
TABLE 124. CIPLA LTD: COMPANY SNAPSHOT
TABLE 125. CIPLA LTD: PRODUCT SEGMENTS
TABLE 126. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 127. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗勃起不全（ED）治療薬のグローバル市場2023：シルデナフィル（バイアグラ）、バルデナフィル（レビトラ、スタキシン）、タダラフィル（シアリス）、アバナフィル（ステンドラ）、ウデナフィル（ザイデナ）、その他
  • ジェネリック医薬品のグローバル市場（2023-2032）：心血管、感染症、がん、糖尿病、その他
  • 抗肥満薬のグローバル市場（2023-2032）：処方薬、市販薬
  • 神経芽腫治療薬のグローバル市場（2023-2032）：化学療法、免疫療法、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP102 )"勃起不全治療薬のグローバル市場（2023-2032）：シルデナフィル、タダラフィル、ウデナフィル、アバナフィル、その他" (英文：Erectile Dysfunction Drugs Market By Products (Sildenafil, Tadalafil, Udenafil, Avanafil , Others), By Mode of Administration  (Oral Medication , Injectable Medication ), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。